



Request for Proposal (RFP) on Current and Emerging Therapies in ER+/HER-Advanced or Metastatic Breast Cancer (mBC)

1. Overview

Rigel Pharmaceuticals, Inc. (Rigel) is committed to supporting independent medical education (IME) activities that are high-quality, fair-balanced, objective, and evidence-based. Through these educational initiatives, Rigel seeks to advance understanding of disease mechanisms and treatment approaches within our therapeutic areas of interest and their impact on patient care.

The intent of this Request for Proposal (RFP) is to notify experienced and eligible medical education providers that Rigel is interested in receiving applications for IME activities pertinent to metastatic breast cancers and aligned to the areas of interests outlined below. The purpose is to bring awareness and knowledge to healthcare professionals focused on the evolving treatment landscape and disease management for patients with ER-positive/HER-negative metastatic breast cancer.

Applicants are encouraged to identify and address the educational needs, barriers, and gaps for patients with ER-positive/HER-negative metastatic breast cancer relating to treatments paradigms, targeted therapies, and future horizons, with a focus on sequencing strategies following progression on endocrine therapy and CDK4/6 inhibitors, including management of endocrine resistance, different therapeutic classes and their mechanism of actions in second or later lines of therapy, management of adverse events, and quality of life.

Proposed activities should focus on increasing clinicians' knowledge, confidence, and competence in caring for patients, specifically in the community setting.


Unless otherwise noted on www.rigel.com/pipeline/independent-medical-education, during the period of this RFP and throughout the year, Rigel will also accept requests from eligible organizations that are not in response to this RFP. Should those grant applications be received during the time of this RFP and align with the parameters outlined in this announcement, Rigel will review those applications and evaluate them according to the same quality and eligibility standards.

Rigel will not control or influence the content, faculty, educational methods, or conclusions of any supported activity. Grant recipients will retain full responsibility for the development and implementation of the educational program.

2. Geographic Scope/Location of Project

The educational program should focus on learners based in the United States.

3. Key Milestones and Dates



4. Funding Range and Project Length

Individual projects requesting up to \$250,000 (inclusive of all direct and indirect costs) will be considered. Both single-support and multi-support grant applications will be considered.

5. Applicant Eligibility Criteria

The following applicants may apply:

- Healthcare institutions and medical centers/hospitals
- Medical, nursing, allied health, and/or educational institutions
- Professional organizations/medical societies and associations
- Medical education companies

Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).

Requesting organizations must be legally able to receive the funding award directly from Rigel Pharmaceuticals, Inc. We strongly recommend that applicants confirm this with their organization or institution prior to applying. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Rigel Pharmaceuticals may be subject to rescission.

For projects offering continuing education credit, the requesting organization must be accredited.

6. Areas of Interests and Program Types

The goal of this RFP is to support education for healthcare professionals and advanced practitioners working in the oncology setting caring for patients with ER-positive/HER-negative metastatic breast cancer. Proposed educational activities should focus on increasing the understanding of emerging mechanisms of action (MOA) of novel agents, practice-changing clinical updates for mBC and how to incorporate them safely and effectively for appropriate patients, particularly in the post CDK4/6 inhibitor(s) ESR1 MBC setting.



Projects for this grant program will be considered for support if they focus on one or more of the following areas:

- Educate on the current guideline-based treatment options and evolving standards of care for ER-positive/HER2-negative *ESR1m* metastatic breast cancer.
- Educate on the sequencing strategies following endocrine therapy and CDK4/6 inhibitors, including management of endocrine resistance, in patients with *ESR1m* metastatic breast cancer.
- Increase understanding of differences in mechanisms of action among emerging and available endocrine therapies, including PROTAC ER degraders, SERDs, and other relevant therapeutic approaches.
- Increase understanding of clinically relevant differences among available targeted therapies for ER+/HER2-, *ESR1m* metastatic breast cancer, including differences in mechanism of action, efficacy, safety, and other evidence-based treatment considerations.
- Educate on the management of treatment-related toxicities and incorporate quality of life, adherence, comorbidities, and patient preferences into shared decision-making.

Examples of educational formats that will be considered for this RFP include but are not limited to:

- On-agenda educational sessions during live conferences. Examples include but not limited to ASCO, JADPRO, SABCS, ESMO, SABO, IBC, and ONS
- Conference coverage reviews, including expert interviews recorded at live conferences
- Interactive Case-Based Hubs and workshops
- Tumor boards
- Point-of-Care Digital Toolkits
- Regional/Local Workshop series
- Expert interviews
- Online articles, newsletter articles, training courses, webinars
- Social media posted & linked content
- Videos, podcasts, infographics, and animations
- Note: Based on educational format, enduring materials (online articles, newsletter articles, training courses, podcast, webinars, etc.) are required.

7. Target Audience/Learners

The intended target audience may include medical oncologists, pharmacists, nurses and other healthcare professionals on the multidisciplinary care team in both the community and academic setting responsible for the treatment decisions for, and care of, patients with breast cancer with a particular focus on community learners.

8. Outcomes Measures

Up to Moore's Level 4 outcomes are expected.

9. Application and Notification Detail

Rigel Pharmaceuticals, Inc.'s Independent Medical Education Grant
Request for Proposal



Grant applications must be submitted via email to grants@rigel.com by the date shown above.

Requests are evaluated using objective criteria, including alignment with an identified educational need, scientific rigor, independence, anticipated educational impact, proposed budget, and the applicant's qualifications and ability to execute the proposed activity.

Applicants may be asked for additional clarification during the review period.

All applicants will be notified via email by the dates noted above.

10. Questions

If you have questions regarding this RFP or the application process, please send an email to the Rigel Independent Medical Education Grants Team at grants@rigel.com.